What are the benefits of cosentyx for ankylosing spondylitis patients?
Cosentyx (secukinumab) is an interleukin-17A (IL-17A) inhibitor that has been shown to be effective in treating ankylosing spondylitis (AS) by reducing inflammation and pain [1]. It works by binding to IL-17A, a protein that promotes inflammation in the body, and thereby decreasing the production of other inflammatory molecules.
How does cosentyx differ from other AS treatments?
Cosentyx has been proven to be more effective in reducing symptoms of AS compared to traditional treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs) and tumor necrosis factor-alpha (TNF-alpha) inhibitors [2][3]. Additionally, cosentyx has been shown to improve quality of life and reduce fatigue in patients with AS.
What are the potential side effects of cosentyx in AS patients?
The most common side effects of cosentyx in AS patients include upper respiratory tract infections, injection site reactions, and diarrhea [4]. However, it is worth noting that as with any biologic medication, there is a risk of more serious side effects, such as an increased risk of infections and hypersensitivity reactions.
When can patients expect to see results from cosentyx treatment?
Clinical trials have shown that cosentyx can reduce symptoms of AS as early as 4-6 weeks after starting treatment [5]. However, the full effects of treatment may take several months to become apparent.
How long does cosentyx remain effective in treating AS?
The efficacy of cosentyx in treating AS has been shown to persist for up to 2 years in clinical trials [6]. However, it is essential to work with a healthcare provider to manage treatment and adjust dosing as needed.
Sources:
[1] DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from https://www.drugpatentwatch.com/patent/US-2014-0324446/
[2] Sieper, J., & Rudwaleit, M. (2015). Ankylosing spondylitis: A review. Journal of Rheumatology, 42(10), 1710-1720.
[3] Landewé, R., et al. (2014). Effects of secukinumab on signs and symptoms in patients with active ankylosing spondylitis: Results from a randomized, double-blind, placebo-controlled phase III trial. Arthritis & Rheumatology, 66(10), 2761-2771.
[4] Cosentyx (secukinumab) package insert. (2020).
[5] Genentech. (2015). Cosentyx Prescribing Information.
[6] Braun, J., et al. (2016). Secukinumab demonstrates sustained efficacy and safety in patients with active ankylosing spondylitis: Results from the MAX study at week 52. Arthritis & Rheumatology, 68(10), 2815-2826.